# A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

> **NCT04943497** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2424 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** ribociclib
- **OTHER:** aplelicib
- **OTHER:** mono endocrine therapy
- **OTHER:** chemotherapy

## Key facts

- **NCT ID:** NCT04943497
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-27
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-07-28
- **Target enrollment:** 2424 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943497, "A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04943497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*